EMA Gives Positive Opinion on Zoetis Inc. (ZTS)' Cat Arthritis Therapy, Portela

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Zoetis Inc. is one of them.

Zoetis Inc. (NYSE:ZTS) continues to strengthen its position as a global leader in animal health, with steady growth and expanding innovation. The company develops medicines, vaccines, and diagnostics for both livestock and companion animals, and its diverse product portfolio has driven consistent revenue gains of about 4.2% year over year. The corporation’s financial resilience is underscored by a strong return on equity above 55%, free cash flow exceeding $2.2 billion, and a dividend yield of roughly 1.3%, supported by a conservative payout ratio.

A key development for Zoetis Inc. (NYSE:ZTS) is its collaboration with Blacksmith Medicines to advance new antibiotics aimed at combating antimicrobial resistance in veterinary care, positioning the company at the forefront of a growing global challenge. At the same time, Zoetis is expanding in the companion animal market with innovative treatments. In September 2025, its arthritis therapy for cats, Portela (relfovetmab), received a positive opinion from the European Medicines Agency, reflecting the business’s commitment to addressing unmet needs in pet health.

Financially, Zoetis Inc. (NYSE:ZTS) has outperformed expectations, posting quarterly earnings per share of $1.76, above the $1.62 estimate, and setting full-year guidance at $6.30–$6.40.

While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.